Lilly: Study shows Alimta has fewer side effects than rival

... Lilly: Study shows K.

Wall AP Business AP Technology Sports Entertainment Indiana Living Obituaries Weather | Traffic CustomerServices SubscriberServices INtake Community Fact Files MessageBoards Multimedia/Photos Newsletters Star Source Send us yournews tips, ideas Star Links Links mentionedin The Star Star Headlines Get RSS feedof latest news 7 days Archive Lilly: Study shows In the 571-patient study, those given The Lilly-sponsored research was presented at the meeting of the European Society for Medical Oncology in Vienna, ...

Alimta approved as first treatment for Mesothelioma, a deadly ...

... News-Medical.Net...

Medical News From Around The World Materials Nanotechnology Medical News Categories Legals Medical Books Medical Conferences Notable Publications News-Medical.Net Pemetrexed is the first licenced treatment for malignant pleural mesothelioma, in combination with cisplatin.

Most mesothelioma patients have a life expectancy of five months at the time of diagnosis.

In a recent clinical trial, patients treated with pemetrexed and cisplatin lived longer than tho...

INDIANAPOLIS, November 1/PRNewswire/

... Europa Press Usuario: Password: Entrar Buscador: Noticias Cotizaciones Buscar ActualidadFinanzasDeportesAgendasInformaciónMultimediaComunicaciónContáctenosCatálogo Política Justicia Internacional Iberoamérica Sociedad Salud Comunicados Lenguas Destacados Sociedad de la información Te Ofrece Canal Energía Te Ofrece Canal Turismo Te ofrece Canal Deportes Te ofrece La Cultura Comunicados Internet COMUNICADO: Lung Cancer Patients May Benefit From More Time Without Life-Threatening Chemotherapy Side Effects INDIANAPOLIS, November 1/PRNewswire/ New data presented today confirm that advanced lung cancer patients canlook forward to better-quality survival when treated with Eli Lilly and Company announced theresults of this analysis today at the 29th annual European Society forMedical Oncology meeting in Vienna, Austria.

"Patients suffer from two things, the cancer and chemotherapy sideeffects.

They do not want to live their lives from doctors' clinics orhospital beds - that's what makes these data so meaningful," said Jean-LouisPujol, M.D., head of the department of thoracic oncology, MontpellierAcademic Hospital, France.

"These results reinforce

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news